Research LetterGenotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapyMoranguinho, Inêsa; Borrego, Pedroa,b; Gonçalves, Fátimac; Gomes, Perpétuac,d; Rocha, Josée; Barreto, Jorgef; Taveira, Nunoa,dAuthor Information aResearch Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa bCentro de Administração e Políticas Públicas (CAPP), Instituto Superior de Ciências Sociais e Políticas (ISCSP) da Universidade de Lisboa cServiço de Patologia Clínica, Laboratório de Biologia Molecular, Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz, Lisboa dCentro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz (IUEM), Caparica, Portugal eNúcleo de Apoio Técnico fPrograma de Luta contra as Doenças de Transmissão Sexual, Incluindo VIH/Sida, Praia, Cabo Verde. Correspondence to Nuno Taveira, Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal. E-mail: email@example.com Received 5 September, 2019 Revised 18 October, 2019 Accepted 21 October, 2019 Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com). AIDS: March 1, 2020 - Volume 34 - Issue 3 - p 483-486 doi: 10.1097/QAD.0000000000002431 Buy SDC Metrics Abstract The pol gene from HIV-2-infected patients from Cape Verde experiencing virologic failure was sequenced and drug resistance mutations were determined. Most patients were taking a first-line regimen of zidovudine (AZT), lamivudine (3TC) and lopinavir/ritonavir (LPV/r). Resistance mutations were found in most patients (11/17; 64.7%) especially I82F (4/7; 57.1%) and M184V (10/17; 58.8%). Resistance to all reverse transcriptase and protease inhibitors was found in 58.8% (10/17) of the patients. Integrase inhibitors are warranted to treat these patients. Copyright © 2020 Wolters Kluwer Health, Inc.